Independent Satellite Symposia
Approaches for Optimal Molecular Testing, Treatment, and Management of NSCLC and Accompanying Driver Mutations
Friday, October 8, 2021
8:30AM – 9:45AM ET
7:00PM – 8:15PM ET
1.25 CME/CNE/AAPA/AANP/CPE Credits
Learning Objectives:
- Implement guideline-directed recommendations for NSCLC detection, staging, molecular classification, and treatments
- Identify the strengths and limitations of molecular testing methodologies and genomic biomarkers for NSCLC identification, prognosis, and risk stratification
- Evaluate the pharmacology, safety, and efficacy of new and emerging immunotherapies, targeted therapies, and treatment combinations for the management of NSCLC
- Describe the pathophysiological role of EGFR mutations in NSCLC and implement the most up-to-date management options for treating patients with this driver mutation into clinical practice
Speakers 
Marianne Davies, DNP, ACNP, AOCNP, FAAN
Associate Professor
Yale School of Nursing
Oncology Nurse Practitioner-Thoracic & Solid Tumor
Yale Comprehensive Cancer Center
West Haven, Connecticut 
Justin Gainor, MD
Director, Center for Thoracic Cancers
Director, Targeted Immunotherapy
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
CLL/SLL: Managing Adverse Events Associated with BTK Inhibitor Therapy
Sunday, October 10, 2021
8:30AM – 9:45AM ET
6:30PM – 7:45PM ET
1.25 CME/CNE/AAPA/AANP/CPE Credits
Learning Objectives:
- Describe factors that influence first- and second-line therapeutic sequencing in CLL/SLL, as well as current recommendations from appropriate treatment guidelines
- Evaluate the most recent clinical efficacy and safety data surrounding BTK inhibitors for the treatment of CLL/SLL
- Assess treatment barriers associated with use of BTK inhibitors in CLL/SLL including adverse events and potential implications due to the combination of targeted therapies
- Implement strategies through collaboration with a multidisciplinary care team for the optimal management of adverse events associated with BTK inhibitor therapy
Speakers 
Lisa Nodzon, PhD, ARNP, AOCNP
Advanced Registered Nurse Practitioner
Malignant Hematology Department
Moffitt Cancer Center
Tampa, Florida 
Javier Pinilla Ibarz, MD, PhD
Senior Member, Head of the Lymphoma Section
Director of Immunotherapy
Malignant Hematology Department
Moffitt Cancer Center
Tampa, Florida
Supported by an educational grant from Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
Navigating the Expanding Treatment Landscape in Metastatic Urothelial Cancer: Novel Targeted Therapies
Wednesday, October 13, 2021
10:30AM – 11:45am ET
5:00PM – 6:15PM ET
1.25 CME/CNE/AAPA/AANP/CPE Credits
Learning Objectives:
- Assess evidence-based guidelines and recent safety and efficacy data of first-line, second-line, and subsequent-line therapies for the treatment of mUC
- Evaluate the profiles of antibody-drug conjugates for the treatment of mUC, including mechanisms of action, efficacy, safety, and potential treatment benefits
- Apply strategies to appropriately utilize antibody-drug candidates in clinical practice for the treatment of mUC according to current guideline recommendations
- Implement patient-centered care and education strategies to address treatment barriers, adverse events, and healthcare disparities in mUC
Speaker 
Petros Grivas, MD, PhD
Physician
Seattle Cancer Care Alliance
Associate Professor, Division of Medical Oncology
University of Washington School of Medicine
Clinical Director, Genitourinary Cancers Program
University of Washington Medicine
Associate Professor, Clinical Research Division
Fred Hutchinson Cancer Research Center
Seattle, Washington
Nerina T. McDonald, PA-C
Physician Assistant
Seattle Cancer Care Alliance
Physician Assistant
University of Washington Medicine
Seattle, Washington
Supported by an educational grant from Astellas and Seagen Inc.
Navigating the Evolving Treatment Landscape in Prostate Cancer: A Focus on Novel Anti-androgen Therapy
Friday, October 15, 2021
8:30AM – 9:45AM ET
7:45PM ET – 9:00PM ET
1.25 CME/CNE/AAPA/AANP/CPE Credits
Learning Objectives:
- Assess the strengths and limitations of current treatment guidelines and management strategies to optimize anti-androgen therapy and patient outcomes
- Evaluate the latest clinical data from randomized controlled trials (RCTs) investigating current and emerging anti-androgen therapies in castration-resistant PC (CRPC) and hormone-sensitive PC (HSPC)
- Implement strategies to anticipate and manage adverse events (AEs) associated with anti-androgen therapy
- Describe the optimal role of APs in PC management
Speakers 
Brenda Martone, MSN, ANP-BC, AOCNP
Nurse Practitioner
Robert H Lurie Comprehensive Cancer Center
Northwestern Medicine
Chicago, Illinois 
Alicia K. Morgans, MD, MPH
Faculty in Medicine
Harvard Medical School
Genitourinary Medical Oncologist
Medical Director, Survivorship Program
Dana-Farber Cancer Institute
Boston, Massachusetts
Supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
Metastatic HER2-Positive Breast Cancer: Newer and Emerging Treatment Considerations and Personalized Therapies
Sunday, October 17, 2021
8:30AM – 9:45AM ET
8:00PM ET – 9:15PM ET
1.25 CME/CNE/AAPA/AANP/CPE Credits
Learning Objectives:
- Evaluate current standards of care for HER2+ early-stage and metastatic breast cancer
- Assess the importance of screening and biomarker testing to identify appropriate treatment options for patients with metastatic HER2+ breast cancer
- Identify recently approved and emerging therapies in advanced HER2+ breast cancer along with key updates to clinical data, including efficacy for treating brain metastases
- Apply strategies to appropriately sequence HER2-targeted regimens in first-, second-, and subsequent-line settings according to current data and recommendations
Speakers 
Melissa Rikal, MSN, FNP-BC
Nurse Practitioner
Tennessee Oncology
Oncology/Drug Development Unit
Sarah Cannon Research Institute
Nashville, Tennessee 
Lee Schwartzberg, MD, FACP
Medical Director, West Cancer Center
Chief Medical Officer, OneOncology
Professor of Medicine
University of Tennessee Health Science Center
Nashville, Tennessee
Supported by an educational grant from Seagen Inc.